AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
DOLUTEGRAVIR AND LAMIVUDINE
4 registrations across 3 African markets— 3 active
Markets with DOLUTEGRAVIR AND LAMIVUDINE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| DOLUTEGRAVIR AND LAMIVUDINE TABLETS TABLETS | 🇷🇼Rwanda | CIPLA LIMITED | active | Feb 2030 |
| DOLUTEGRAVIR_AND_LAMIVUDINE 50/300MG TABLET TABLET | 🇲🇼Malawi | — | expired | Mar 2024 |
| Dolutegravir and Lamivudine Tablets 50 mg/300 mg Tablets | 🇹🇿Tanzania | Hetero Labs Limited | active | — |
| DOLUTEGRAVIR AND LAMIVUDINE Tablets | 🇹🇿Tanzania | Cipla Limited | active | — |
DOLUTEGRAVIR AND LAMIVUDINE in Africa — Regulatory Overview
DOLUTEGRAVIR AND LAMIVUDINE is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Malawi, Rwanda. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 3 (75%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.